Angiogenix Inc.
This article was originally published in Start Up
Executive Summary
Angiogenix believes the delivery of its novel growth factor, pleiotrophin, will lessen the need for repeated interventional procedures to treat restenosis at a fraction of the current cost of interventional (device or surgical) therapy, without the use of a permanent device or foreign graft.